India’s Department of Biotechnology (DBT) is developing plans to introduce “regulatory sandboxes” for the pharmaceutical sector to fast-track approvals and shorten drug development timelines.
A sandbox would allow innovators to test drug products with more relaxed regulatory requirements. The goal of this initiative is to facilitate earlier, structured interaction between innovators and the Central Drugs Standard Control Organisation (CDSCO). The plan is to reduce uncertainty and accelerate reviews starting from the initial drug application stage. Additionally, faster coordination with the CDSCO could help address lengthy clinical trial requirements and timelines that increase development costs — and thus potentially lead to shorter time to market, especially for innovative products.
The initiative is framed as aligning India with similar international programs, such as expedited approval pathways and innovation task forces run by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA). This is in line with India’s broader harmonization efforts through the International Council for Harmonisation (ICH).
The program is awaiting formal approval from DBT and the Ministry of Science and Technology before going into effect.
Written by: Ames Gross – President and Founder, Pacific Bridge Medical (PBM)
Mr. Gross founded PBM in 1988 and has helped hundreds of medical companies with regulatory and business development issues in Asia. He is recognized nationally and internationally as a leader in the Asian medical markets. Mr. Gross has a BA degree, Phi Beta Kappa, from the University of Pennsylvania and an MBA from Columbia University.